CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for
Related News
FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patients
SPECIALIZED PRESS Friday - October 23, 2020 Bitte JavaScript aktivieren / Please enable JavaScript About Bayer Bayer is a global enterprise with core competencies in the...
Public Technologies 2020-10-23Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
CAMBRIDGE, Mass., Oct. 23, 2020 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has...
PR Newswire 2020-10-232020 Report on Companion Diagnostics in the COVID-19 Era: Market Analysis and Opportunities - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 23, 2020-- The report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive market analysis and business...
The Marshall News Messenger
2020-10-23
BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 PATIENTS IN SOUTH AFRICA
Bergen, Norway - 21 October 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet...
Public Technologies 2020-10-21BerGenBio Virtual R&D Day - 06 November 2020
BERGEN, Norway, Oct. 23, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for...
PR Newswire 2020-10-23Allarity Therapeutics Provides Update on Dovitinib Program
Press release Hørsholm, Denmark (23 October 2020) - Allarity Therapeutics A/S ('Allarity' or the 'Company') today announced several updates related to its planned filing of...
Public Technologies 2020-10-23Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib ...
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target...
Tyler Morning Telegraph
2020-10-21
Related News
FoundationOne®CDx Receives FDA-Approval as a Companion Diagnostic for VITRAKVI®(larotrectinib) to Identify Patients with NTRK Fusions ...
The Marshall News Messenger
2020-10-23